Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
We report the design of the NHS-Galleri trial (ISRCTN91431511), aiming to establish whether a multi-cancer early detection (MCED) test that screens asymptomatic individuals for cancer can reduce late-stage cancer incidence. This randomised controlled trial has invited approximately 1.5 million persons and enrolled over 140,000 from the general population of England (50–77 years; ≥3 years without cancer diagnosis or treatment; not undergoing investigation for suspected cancer). Blood is being collected at up to three annual visits. Following baseline blood collection, participants are randomised 1:1 to the intervention (blood tested by MCED test) or control (blood stored) arm. Only participants in the intervention arm with a cancer signal detected have results returned and are referred for urgent investigations and potential treatment. Remaining participants in both arms stay blinded and return for their next visit. Participants are encouraged to continue other NHS cancer screening programmes and seek help for new or unusual symptoms. The primary objective is to demonstrate a statistically significant reduction in the incidence rate of stage III and IV cancers diagnosed in the intervention versus control arm 3–4 years after randomisation. NHS-Galleri will help determine the clinical utility of population screening with an MCED test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Marteau, T. M., & Bekker, H. (1992) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1992.tb00997.x · Cited by 3,238 · cited 1×
“The questionnaires will include measures designed to assess the psychological consequences of receiving the test result (using the Spielberger State/Trait Anxiety Inventory-6 (STAI-6) and the Psychological Consequences of Screening Questionnaire (PCQ)) [39,40].”
MethodScreening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Harper, D. M., Kemper, A. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.5989 · Cited by 2,509
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., Seiden, M. V., Liu, M. C., Oxnard, G. R., Klein, E. A., Smith, D., Richards, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.011 · Cited by 1,495 · cited 1×
“Sensitivities per cancer type per stage were based on CCGA substudy 2 [45].”
MethodSelf-citationJacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048 · cited 1×
“In the context of previous cancer screening trials, in which it took 10–15 years to generate results, this is incredibly rapid [61,62].”
BackgroundData Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)
Herbert, A., Wijlaars, L., Zylbersztejn, A., Cromwell, D., & Hardelid, P. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx015 · Cited by 742 · cited 15×
“Yet, in England in 2017, only 6% of all cancers were detected through National Health Service (NHS) screening programmes and 46% of all cancers with a known stage were detected at a late stage (III and IV) [7,8].”
BackgroundMethodInfluentialMenon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00731-5 · Cited by 730
Field, J. K., Vulkan, D., Davies, M. P. A., Baldwin, D. R., Brain, K. E., Devaraj, A., Eisen, T., Gosney, J., Green, B. A., Holemans, J. A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100179 · Cited by 230
Cited by
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study
Schrag, D., Beer, T. M., McDonnell, C. H., Nadauld, L., Dilaveri, C. A., Reid, R., Marinac, C. R., Chung, K. C., Lopatin, M., Fung, E. T., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01700-2 · Cited by 396
Circulating tumour cells for early detection of clinically relevant cancer
Lawrence, R., Watters, M., Davies, C. R., Pantel, K., & Lu, Y.-J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00781-y · Cited by 370
Sarcoma care in the era of precision medicine
Wallander, K., Öfverholm, I., Boye, K., Tsagkozis, P., Papakonstantinou, A., Lin, Y., & Haglund de Flon, F. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13717 · Cited by 30
“There is a growing number of studies describing how analysis of cell-free DNA can be utilized for sarcoma diagnostics [157], treatment monitoring [158], identification of resistance mechanisms [159], and minimal residual disease detection [160].”
Background
Metadata
- Authors
- Neal, R. D., Johnson, P., Clarke, C. A., Hamilton, S. A., Zhang, N., Kumar, H., Swanton, C., & Sasieni, P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-10-01
- Volume
- 14
- Issue
- 19
- Pages
- 4818
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4303613649
- Cited by
- 187
- References
- 9
- FWCI
- 11.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.